Extrapolating the absolute dosing and serum levels from mice to humans is challenging, though in TSC mice models, moderate doses of rapamycin (3 mg/kg/d) were shown to lower P-S6 at levels comparable with controls, while high doses (10 mg/kg/d) completely inhibit P-S6 expression [155]. The gene discussed is TAS2R63P; the disease is tuberous sclerosis.